Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Bruker Corporation (BRKR) is a scientific instruments company. The Zacks Consensus Estimate for its current year earnings has been revised 7.3% downward over the last 60 days.Commercial Metals Company (CMC) is a metals processing company. The Zacks Consensus Estimate for its current year earnings has been revised 14.5% downward over the last 60 days.Concentrix Corporation (CNXC) is a customer experience management company.The Zacks Co ...

Bruker Corporation (BRKR) recently announced a new technology, EpicIF (Enhanced photobleaching in cyclic immunofluorescence), to further enhance the CellScape Precise Spatial Proteomics platform for highly multiplexed immunofluorescence (IF).The new technology is likely to enhance the CellScape platform by expanding antibody compatibility and doubling throughput while maintaining tissue integrity and lack of cross-reactivity.Likely Trend of BRKR Stock Following the NewsFollowing the announcement, shares of ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the transition period from to Commission File Number 000-30833 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 04-3110160 (State or other j ...

Bruker Corporation (BRKR) delivered adjusted earnings per share (EPS) of 60 cents for the third quarter of 2024, down 18.9% year over year. The figure missed the Zacks Consensus Estimate by 1.6%. The adjustments include expenses related to the amortization of purchased intangibles, acquisition-related costs and restructuring costs, among others.GAAP EPS was 27 cents compared with 60 cents in the year-ago period.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Following the earnings ann ...

| --- | --- | |------------------------------------------------------------------------------------------------------------|-------| | | | | Q3 2024 Earnings Presentation BRUKER CORPORATION (NASDAQ: BRKR) | | | November 5, 2024 Frank H. Laukien, President & Chief Executive Officer | | | Gerald Herman, Executive Vice President & Chief Financial Officer Joe Kostka, Director, Investor Relations | | BRUKER CORPORATION Safe Harbor Statement Any statements contained in this presentation which do not describe hist ...

Bruker Corporation (NASDAQ:BRKR) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Joe Kostka - Director, Investor Relations Frank Laukien - President and CEO Gerald Herman - Executive Vice President and CFO Conference Call Participants Puneet Souda - Leerink Partners Michael Ryskin - Bank of America Patrick Donnelly - Citi Rachel Vatnsdal - JPMorgan Tycho Peterson - Jefferies Josh Waldman - Cleveland Research Dan Brennan - TD Cowen Brandon Couillard - Wells Fargo Luke Sergot ...

Exhibit 99.1 Bruker Reports Third Quarter 2024 Financial Results • Q3 2024 revenues of $864.4 million, up 16.4% year-over-year (yoy); Bruker organic revenue up 3.1% yoy, and CER revenue up 15.7% yoy; BSI segment organic revenue up 3.8% yoy • Q3 2024 GAAP diluted EPS $0.27; non-GAAP diluted EPS $0.60 • Updated FY2024 guidance: o Revenue $3.34 to $3.37 billion, implying Bruker organic revenue growth of 3% to 4%, and CER revenue growth of approximately 13% yoy o Non-GAAP EPS of $2.36 - $2.41 BILLERICA, Massach ...

Biognosys' proprietary P2 Plasma Enrichment System enables plasma proteome profiling with unprecedented depth and throughput, both as contract research and in-house via licensing By offering the combination of NULISA™ affinity-based assays and TrueDiscovery® mass spectrometry-based plasma profiling with P2 Plasma Enrichment, Biognosys offers the industry's most comprehensive solutions for plasma proteomics Spectronaut® workflows for high-performance computing environments, post-translational modifications, ...

Bruker Corporation (BRKR) recently announced the release of its latest innovative neuroscience research solution, the OptoVolt module, at the Neuroscience 2024 conference. The module uniquely addresses the challenges of voltage imaging by providing scanner technology. The latest release expands Bruker's Ultima multiphoton microscope platform with advanced neuroscience research capabilities. BRKR's Likely Stock Trend Following the News Subsequent to the news, the share price of BRKR moved south 1.6% to $65.9 ...

Bruker Corporation's (BRKR) growth is backed by strong sales within its X-Ray and Nano Analytics businesses. Within the PCI division, expanding customer demand for pre-clinical MRI systems is highly encouraging. Meanwhile, the impact of macroeconomic pressure and currency fluctuation is likely to hurt the company's operational results. In the past year, this Zacks Rank #3 (Hold) company's shares have gained 10.4% compared with the industry's 27.5% growth and the S&P 500 composite's 34.9% gain. This renowned ...